The Snapchat owner will raise $3.2bn if it floats at the top of its range, and shareholders that could include Tencent, Alibaba and Yahoo will sell 45 million shares in the offering.

The Merck & Co-backed antibody developer had secured $100m in equity and debt but has withdrawn plans for an IPO that would have raised $54m at the top of its range.

The Baidu-backed photo and video-sharing app, which is reportedly valued at $3bn, is planning to go public in the US in the second half of 2017.

Alibaba, Tencent and Yahoo are all set to exit the $25bn 'camera company' in what could be the biggest initial public offering for a tech company in more than two years.

Intel and Itochu-backed ForeScout Technologies has confidentially filed for an initial public offering, a year after closing a $76m round that valued it at $1bn.

Celgene and Pharmstandard scored exits as part of an initial public offering in which immuno-oncology company Jounce floated above its range.

AnaptysBio, which filed for the IPO in 2015, has gone public in an offering that will give long-term investor Novo an exit.

Novo and Merck Group have exited ObsEva in an offering that involved the reproductive health treatment developer floating in the middle of its range.

The reproductive health therapy developer, which has raised more than $93m from backers including Novo and Merck Group, has set the terms for its initial public offering.

Knightscope, backed by NTT Docomo, Konica Minolta and Flextronics, has opted for a regulation A+ offering that enables members of the public to buy shares.